iBB researchers have recently established an innovative xenogeneic-free platform to manufacture human mesenchymal-stromal-cell-derived extracellular vesicles (MSC-EVs) at clinically relevant numbers for therapeutic applications.
The team implemented a microcarrier-based stirred tank reactor system to continuously harvest EVs and enhance production yields. Supported by human platelet lysate supplements (in collaboration with AventaCell BioMedical Corp. Ltd), this setup enables efficient MSC expansion and EV production, while preserving cellular identity of MSC. With the integration of a scalable downstream process, the platform ensures the isolation of high-purity EVs in large quantities.
These findings represent an advance towards making MSC-EV-based therapies both cost-effective and accessible for widespread clinical use.
Link to paper: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04341-2